Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands

This publication has 16 references indexed in Scilit:

• Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
  Journal of Hematology & Oncology, 2011
• 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
  European Journal of Cancer, 2011
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
  The Lancet, 2010
• Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
  Clinical Cancer Research, 2009
• A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
  Annals of Oncology, 2008
• Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
  Journal of Clinical Oncology, 2008
• Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
  New England Journal of Medicine, 2004
• Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
  New England Journal of Medicine, 2004
• Preclinical Evaluation of New Taxoids
  Current Pharmaceutical Design, 2001
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
  Journal of Clinical Oncology, 1996